BeiGene to develop $330 million biologics plant
March 7, 2017Manufacturing and Production, Research and Development BeiGene, China, Guangzhou
BeiGene, a Chinese biotech company, and Guangzhou GET Technology Development, an affiliate of Guangzhou Development District, will partner in the …
Researchers discover worrying new antibiotic-resistance gene variant
March 7, 2017Manufacturing and Production, Research and Development drug resistance
A new variant of a human gene which is known to cause significant drug resistance in patients has been discovered …
Cadila and Supernus settle patent dispute over epilepsy generic
March 7, 2017Manufacturing and Production, Sales and Marketing Cadila, Supernus, Trokendi XR, Zydus Cadila
A patent dispute between Indian pharmaceutical firm Cadila Healthcare and US-based Supernus Pharmaceuticals has been ended with legal calls for …
Merck’s Allergopharma opens €42m biopharmaceutical plant
March 7, 2017Manufacturing and Production Allergopharma, Merck
Allergopharma, a subsidiary of Germany’s Merck, has completed construction on its new €42 million biopharmaceutical facility and declared it open …
Vermont senators call for restraints on “beautiful” pharma advertising
March 6, 2017Manufacturing and Production, Sales and Marketing Bernie Sanders, Vermont, pricing
Bernie Sanders is yet again leading the charge against US pharma as Vermont senators have rallied against advertising and marketing …
FDA approves first treatment for excessive night-time urination
March 6, 2017Manufacturing and Production FDA, Noctiva, Serenity
The FDA has approved Noctiva, administered as a nasal spray, for the treatment of people suffering from nocturnal polyuria – …
Negotiating the EU pricing system: How the financial crisis has encouraged closer-knit cooperation between member states
March 6, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Europe, pricing
Drug pricing is a topic that has become headline-friendly over the past year. It has come to dominate media coverage …
Lilly posts impressive psoriasis results in comparison study
March 6, 2017Research and Development, Sales and Marketing J&J, JJ, Stelara, Taltz, lilly
Eli Lilly has revealed strong results in a study comparing its psoriasis treatment, Taltz (ixekizumab), to Johnson & Johnson’s Stelara. …
Cipla halts HIV drug production due to delayed government funding
March 6, 2017Sales and Marketing Cipla, HIV, India, Lopinavir
Indian pharmaceutical company Cipla has halted production of its child-friendly antiretroviral HIV treatment Lopinavir (ABT-378) due to the failure by …
UK High Court rules against AbbVie’s Humira patents
March 6, 2017Sales and Marketing AbbVie, Biogen, Fujifilm Kyowa Kirin Biologics, Humira, Samsung Bioepis, biosimilar
The UK High Court has ruled that two of AbbVie patents, related to dosing regimens for rheumatoid arthritis, psoriasis and …
Phase 3 data for Janssen psoriasis drug shows efficacy over Humira
March 6, 2017Research and Development, Sales and Marketing Humira, Janssen, guselkumab, psoriasis
Janssen has revealed new Phase 3 data for its human monoclonal antibody guselkumab in the treatment of adults with moderate …
Otsuka to acquire Neurovance in potential $250 million deal
March 6, 2017Sales and Marketing ADHD, Neurovance, Otsuka Pharmaceuticals
Otsuka Pharmaceuticals, a pharmaceutical firm with headquarters in Japan, has agreed to pay a potential $250 million in a deal …
Bioverativ adds new member to board of directors
March 3, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
Biogen spinout, Bioverativ, have moved to consolidate its board of directors by appointing Anna Protopapas to the board. Protopapas becomes …
Gene therapy: Advanced treatments for a new era
March 3, 2017Medical Communications gene therapy
Aranca discusses the considerable advances that have occured in the last few years in gene therapy.Considerable research has been conducted …
Top Ten most popular articles on Pharmafile.com this week
March 3, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing top ten
It’s been a busy week on Pharmafile.com over the last seven days. Europe’s first biosimilar treatment for cancer continues to …
EU-US reach landmark deal on mutual recognition of manufacturing inspection
March 3, 2017Medical Communications EMA, EU, FDA, US
The European Union and the US has announced that an agreement has been made to mutually recognise inspection of drug …
Price cuts bring 14 Cancer Drugs Fund treatments into routine NHS use
March 3, 2017Medical Communications, Sales and Marketing CDF, NICE
NICE has revealed that it has reached the halfway point in its review of the old Cancer Drugs Fund (CDF) …
CMA accuses Concordia and Actavis of illegal agreement to maintain high prices
March 3, 2017Medical Communications, Sales and Marketing Actavis UK, CMA, Concordia, competition and markets authority
The Competition and Markets Authority (CMA) has alleged that Concordia and Actavis UK entered into a clandestine agreement to maintain …
Ipsen appoints new Executive Vice President
March 2, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ipsen
Ipsen has announced the appointment of Benoit Hennion as Executive Vice President and President of Primary Care. Hennion has worked …
Juno Therapeutics abandons problem leukaemia drug
March 2, 2017Juno Therapeutics has finally called time on the development of its CAR-T therapy, JCAR015, after one of the most turbulent …
Latest content
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care
